TOI ONCOLOGY INSTITUTE INC (THE)

The Oncology Institute Names Minh Merchant Chief Legal Officer

The Oncology Institute Names Minh Merchant Chief Legal Officer

CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare partner to oncology patients and payors.

Ms. Merchant has more than two decades of experience advising public and private healthcare organizations, including significant experience in transactional, regulatory and compliance matters. She previously served as general counsel at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson, and holds a JD from UCLA School of Law.

“We are excited to welcome Minh to TOI as our Chief Legal Officer,” said Daniel Virnich, MD, CEO of The Oncology Institute. “As our footprint and care model continue to grow, she brings the depth of experience to help TOI continue operate as a compliant and secure national oncology platform.”

“I’m thrilled at the opportunity to join TOI at this important juncture in the organization’s growth as a public company,” commented Ms. Merchant. “The organization’s mission to provide better access and affordability to cancer care is inspiring and I feel that I’m well positioned to help TOI continue its successful navigation of the rapidly evolving healthcare legal and regulatory environment.”

About The Oncology Institute ():

Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.

Media

The Oncology Institute, Inc.





Investors

ICR Healthcare



EN
06/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONCOLOGY INSTITUTE INC (THE)

 PRESS RELEASE

The Oncology Institute to Participate in the 25th Annual Needham Healt...

The Oncology Institute to Participate in the 25th Annual Needham Healthcare Conference CERRITOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the 25th Annual Needham Healthcare Conference, being held virtually on Wednesday, April 15, 2026, including a fireside chat at 3:45 p.m. ET. A webcast link of the presentation will be accessible through the Investo...

 PRESS RELEASE

The Oncology Institute Names Minh Merchant Chief Legal Officer

The Oncology Institute Names Minh Merchant Chief Legal Officer CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare par...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: April 4, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Finan...

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026 CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginConti...

 PRESS RELEASE

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Ear...

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI)  a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch